Concepts (298)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 14 | 2024 | 541 | 5.400 |
Why?
|
| Skin | 14 | 2024 | 554 | 3.580 |
Why?
|
| Dermatology | 5 | 2020 | 35 | 2.950 |
Why?
|
| Photochemotherapy | 9 | 2019 | 97 | 2.770 |
Why?
|
| Skin Pigmentation | 5 | 2021 | 40 | 2.540 |
Why?
|
| Melanoma | 5 | 2024 | 454 | 2.000 |
Why?
|
| Education, Medical | 3 | 2021 | 233 | 1.890 |
Why?
|
| Skin Diseases | 5 | 2020 | 166 | 1.850 |
Why?
|
| Photosensitizing Agents | 8 | 2019 | 48 | 1.740 |
Why?
|
| Dermatitis, Atopic | 3 | 2022 | 52 | 1.640 |
Why?
|
| Nevus, Pigmented | 2 | 2023 | 49 | 1.600 |
Why?
|
| Internship and Residency | 4 | 2021 | 1004 | 1.600 |
Why?
|
| Mohs Surgery | 3 | 2020 | 21 | 1.550 |
Why?
|
| Pigmentation Disorders | 2 | 2019 | 13 | 1.430 |
Why?
|
| Nevus | 3 | 2023 | 15 | 1.400 |
Why?
|
| Acne Vulgaris | 3 | 2021 | 32 | 1.370 |
Why?
|
| Scalp Dermatoses | 2 | 2019 | 10 | 1.350 |
Why?
|
| Keratosis, Actinic | 3 | 2018 | 11 | 1.270 |
Why?
|
| Phototherapy | 2 | 2016 | 35 | 1.130 |
Why?
|
| Skin Aging | 2 | 2017 | 28 | 1.130 |
Why?
|
| Humans | 62 | 2024 | 86601 | 0.990 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2023 | 11 | 0.930 |
Why?
|
| Interleukin-4 | 2 | 2021 | 127 | 0.910 |
Why?
|
| Aminolevulinic Acid | 3 | 2019 | 21 | 0.890 |
Why?
|
| Rhinitis, Allergic | 1 | 2022 | 43 | 0.860 |
Why?
|
| Mouth Mucosa | 2 | 2019 | 67 | 0.840 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 2019 | 4 | 0.830 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.770 |
Why?
|
| Ear Neoplasms | 1 | 2020 | 10 | 0.760 |
Why?
|
| Dermatologists | 1 | 2020 | 2 | 0.760 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2020 | 8 | 0.760 |
Why?
|
| Drug Eruptions | 2 | 2021 | 35 | 0.760 |
Why?
|
| Certification | 1 | 2020 | 58 | 0.760 |
Why?
|
| Mucositis | 1 | 2020 | 17 | 0.750 |
Why?
|
| Margins of Excision | 1 | 2020 | 39 | 0.750 |
Why?
|
| Private Practice | 1 | 2020 | 11 | 0.740 |
Why?
|
| Career Mobility | 1 | 2020 | 31 | 0.740 |
Why?
|
| SEER Program | 4 | 2021 | 184 | 0.740 |
Why?
|
| Coronavirus | 1 | 2020 | 19 | 0.730 |
Why?
|
| Hyperpigmentation | 2 | 2017 | 5 | 0.730 |
Why?
|
| Low-Level Light Therapy | 1 | 2019 | 15 | 0.720 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2019 | 2 | 0.720 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2019 | 19 | 0.720 |
Why?
|
| Laser Therapy | 4 | 2015 | 142 | 0.710 |
Why?
|
| Silicone Gels | 1 | 2019 | 3 | 0.710 |
Why?
|
| Bacteremia | 1 | 2020 | 99 | 0.700 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 19 | 0.690 |
Why?
|
| Rejuvenation | 2 | 2016 | 18 | 0.670 |
Why?
|
| Eyelids | 2 | 2016 | 23 | 0.670 |
Why?
|
| Herpes Simplex | 1 | 2020 | 202 | 0.670 |
Why?
|
| MicroRNAs | 2 | 2021 | 534 | 0.660 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2018 | 5 | 0.660 |
Why?
|
| Pandemics | 2 | 2023 | 740 | 0.630 |
Why?
|
| Skin Diseases, Infectious | 1 | 2017 | 13 | 0.630 |
Why?
|
| Pain | 2 | 2019 | 391 | 0.630 |
Why?
|
| Licensure, Medical | 3 | 2021 | 19 | 0.590 |
Why?
|
| Mouth Neoplasms | 1 | 2019 | 194 | 0.590 |
Why?
|
| Dermatologic Agents | 2 | 2017 | 71 | 0.560 |
Why?
|
| United States | 7 | 2022 | 6665 | 0.560 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1169 | 0.550 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2357 | 0.530 |
Why?
|
| Biological Products | 1 | 2017 | 143 | 0.530 |
Why?
|
| Pityriasis Rubra Pilaris | 2 | 2019 | 3 | 0.530 |
Why?
|
| Blepharoplasty | 1 | 2015 | 8 | 0.530 |
Why?
|
| Aspergillosis | 1 | 2015 | 41 | 0.520 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 59 | 0.520 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 977 | 0.520 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.510 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.510 |
Why?
|
| Patient Compliance | 1 | 2016 | 227 | 0.500 |
Why?
|
| Asthma | 1 | 2022 | 955 | 0.500 |
Why?
|
| Condylomata Acuminata | 1 | 2014 | 15 | 0.490 |
Why?
|
| Sweet Syndrome | 2 | 2014 | 5 | 0.480 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 1075 | 0.470 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 45 | 0.470 |
Why?
|
| Epidermis | 3 | 2024 | 100 | 0.450 |
Why?
|
| Female | 23 | 2022 | 44507 | 0.420 |
Why?
|
| Male | 20 | 2022 | 40956 | 0.420 |
Why?
|
| Aged | 11 | 2022 | 18402 | 0.420 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 1565 | 0.400 |
Why?
|
| Middle Aged | 13 | 2020 | 25017 | 0.380 |
Why?
|
| Esthetics | 3 | 2021 | 44 | 0.370 |
Why?
|
| Retrospective Studies | 5 | 2022 | 8475 | 0.370 |
Why?
|
| Antiviral Agents | 1 | 2014 | 510 | 0.360 |
Why?
|
| Heart Transplantation | 1 | 2015 | 705 | 0.360 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 6501 | 0.360 |
Why?
|
| Hand Dermatoses | 1 | 2009 | 9 | 0.350 |
Why?
|
| Dermis | 1 | 2009 | 27 | 0.350 |
Why?
|
| Sarcoidosis | 2 | 2020 | 71 | 0.350 |
Why?
|
| Ultraviolet Therapy | 1 | 2009 | 15 | 0.350 |
Why?
|
| Rare Diseases | 2 | 2019 | 59 | 0.340 |
Why?
|
| Biopsy, Needle | 2 | 2019 | 235 | 0.330 |
Why?
|
| Tomography, Optical Coherence | 3 | 2024 | 130 | 0.330 |
Why?
|
| Color | 2 | 2019 | 81 | 0.310 |
Why?
|
| Curriculum | 2 | 2021 | 539 | 0.290 |
Why?
|
| Administration, Topical | 2 | 2018 | 95 | 0.290 |
Why?
|
| Treatment Outcome | 6 | 2019 | 7988 | 0.280 |
Why?
|
| Severity of Illness Index | 3 | 2023 | 1801 | 0.280 |
Why?
|
| Survival Rate | 2 | 2020 | 1860 | 0.270 |
Why?
|
| Cosmetic Techniques | 2 | 2016 | 28 | 0.270 |
Why?
|
| Biomarkers | 3 | 2021 | 1718 | 0.260 |
Why?
|
| Age Factors | 2 | 2019 | 1849 | 0.250 |
Why?
|
| Infant | 2 | 2022 | 3045 | 0.250 |
Why?
|
| Photoacoustic Techniques | 1 | 2024 | 8 | 0.240 |
Why?
|
| Child | 5 | 2022 | 6926 | 0.230 |
Why?
|
| Purpura | 2 | 2000 | 8 | 0.220 |
Why?
|
| Varicose Ulcer | 1 | 2022 | 6 | 0.220 |
Why?
|
| Biopsy | 3 | 2023 | 1161 | 0.220 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1685 | 0.210 |
Why?
|
| Hidradenitis | 1 | 2021 | 2 | 0.210 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2021 | 13 | 0.210 |
Why?
|
| Incidence | 2 | 2023 | 1576 | 0.210 |
Why?
|
| Communicable Diseases | 1 | 2022 | 63 | 0.210 |
Why?
|
| Bronchogenic Cyst | 1 | 2021 | 5 | 0.200 |
Why?
|
| Insulin Resistance | 2 | 2021 | 377 | 0.200 |
Why?
|
| Dermoid Cyst | 1 | 2021 | 15 | 0.200 |
Why?
|
| Dermoscopy | 1 | 2020 | 5 | 0.200 |
Why?
|
| Up-Regulation | 2 | 2021 | 712 | 0.190 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2020 | 6 | 0.190 |
Why?
|
| Adult | 10 | 2020 | 25640 | 0.190 |
Why?
|
| Staphylococcus epidermidis | 1 | 2020 | 14 | 0.190 |
Why?
|
| Ear, External | 1 | 2020 | 26 | 0.190 |
Why?
|
| Necrobiosis Lipoidica | 1 | 2020 | 2 | 0.190 |
Why?
|
| Accreditation | 1 | 2020 | 60 | 0.190 |
Why?
|
| Personnel Selection | 1 | 2020 | 59 | 0.190 |
Why?
|
| Necrosis | 3 | 2015 | 204 | 0.180 |
Why?
|
| Mannose-Binding Lectins | 1 | 2019 | 6 | 0.180 |
Why?
|
| Tattooing | 1 | 2019 | 5 | 0.180 |
Why?
|
| Mutagens | 1 | 2019 | 31 | 0.180 |
Why?
|
| Panuveitis | 1 | 2019 | 2 | 0.180 |
Why?
|
| Protective Factors | 1 | 2019 | 22 | 0.180 |
Why?
|
| Mastocytoma, Skin | 1 | 2019 | 1 | 0.180 |
Why?
|
| Cultural Diversity | 1 | 2020 | 51 | 0.180 |
Why?
|
| Mastocytoma | 1 | 2019 | 4 | 0.180 |
Why?
|
| Lupus Vulgaris | 1 | 2019 | 4 | 0.180 |
Why?
|
| Corneal Ulcer | 1 | 2019 | 6 | 0.180 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2019 | 3 | 0.180 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1540 | 0.180 |
Why?
|
| Scleritis | 1 | 2019 | 5 | 0.180 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2019 | 6 | 0.180 |
Why?
|
| Paraproteinemias | 1 | 2019 | 13 | 0.180 |
Why?
|
| S100 Proteins | 1 | 2019 | 50 | 0.180 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 276 | 0.180 |
Why?
|
| Antigens, CD1 | 1 | 2019 | 35 | 0.180 |
Why?
|
| Interviews as Topic | 1 | 2020 | 319 | 0.180 |
Why?
|
| Lectins, C-Type | 1 | 2019 | 85 | 0.180 |
Why?
|
| Arthralgia | 1 | 2019 | 36 | 0.170 |
Why?
|
| Antigen-Antibody Complex | 1 | 2019 | 87 | 0.170 |
Why?
|
| Simplexvirus | 1 | 2020 | 151 | 0.170 |
Why?
|
| Microscopy, Electron | 1 | 2019 | 503 | 0.170 |
Why?
|
| Medicare | 1 | 2022 | 406 | 0.170 |
Why?
|
| Minority Groups | 1 | 2020 | 137 | 0.170 |
Why?
|
| Anesthetics, Local | 1 | 2019 | 76 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 860 | 0.170 |
Why?
|
| Vascular Diseases | 1 | 2000 | 119 | 0.170 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 30 | 0.170 |
Why?
|
| Pain Management | 1 | 2019 | 127 | 0.160 |
Why?
|
| Tumor Burden | 1 | 2019 | 288 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 236 | 0.160 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 8 | 0.160 |
Why?
|
| Telemedicine | 1 | 2020 | 169 | 0.160 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 532 | 0.160 |
Why?
|
| Wound Healing | 2 | 2019 | 344 | 0.160 |
Why?
|
| Keratinocytes | 1 | 2018 | 143 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2019 | 458 | 0.160 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 481 | 0.150 |
Why?
|
| Dermatitis, Phototoxic | 1 | 1997 | 2 | 0.150 |
Why?
|
| Motivation | 1 | 2020 | 287 | 0.150 |
Why?
|
| Neutrophils | 3 | 2021 | 307 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1621 | 0.150 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 589 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 857 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 258 | 0.150 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 177 | 0.150 |
Why?
|
| Hospitalization | 1 | 2022 | 848 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 329 | 0.150 |
Why?
|
| Nocardia Infections | 1 | 2016 | 5 | 0.150 |
Why?
|
| Onychomycosis | 1 | 2016 | 1 | 0.140 |
Why?
|
| Intense Pulsed Light Therapy | 1 | 2016 | 1 | 0.140 |
Why?
|
| Doxycycline | 1 | 2016 | 27 | 0.140 |
Why?
|
| Telangiectasis | 1 | 2016 | 6 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2020 | 375 | 0.140 |
Why?
|
| Hirsutism | 1 | 2016 | 61 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 369 | 0.140 |
Why?
|
| Logistic Models | 2 | 2019 | 1185 | 0.140 |
Why?
|
| Sex Factors | 1 | 2019 | 1054 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2021 | 751 | 0.140 |
Why?
|
| Cicatrix | 1 | 2016 | 63 | 0.140 |
Why?
|
| Fluorouracil | 1 | 2017 | 556 | 0.140 |
Why?
|
| Cosmetics | 1 | 2015 | 7 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 763 | 0.130 |
Why?
|
| Life Change Events | 1 | 2015 | 48 | 0.130 |
Why?
|
| Cellulitis | 1 | 2014 | 19 | 0.130 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1753 | 0.130 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 22 | 0.120 |
Why?
|
| Caustics | 1 | 2014 | 4 | 0.120 |
Why?
|
| Cryotherapy | 1 | 2014 | 29 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2232 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2019 | 2378 | 0.120 |
Why?
|
| Prognosis | 1 | 2021 | 3674 | 0.120 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 96 | 0.120 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 141 | 0.120 |
Why?
|
| Child Development | 1 | 2015 | 163 | 0.110 |
Why?
|
| Muir-Torre Syndrome | 1 | 2012 | 4 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 351 | 0.110 |
Why?
|
| Inflammation | 1 | 2018 | 920 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2015 | 237 | 0.110 |
Why?
|
| Facial Neoplasms | 1 | 2012 | 25 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 549 | 0.110 |
Why?
|
| Risk Factors | 4 | 2019 | 5416 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1464 | 0.110 |
Why?
|
| Viral Proteins | 1 | 2014 | 300 | 0.110 |
Why?
|
| Patient Selection | 1 | 2016 | 685 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2019 | 2261 | 0.100 |
Why?
|
| Animals | 6 | 2024 | 26581 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2436 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 746 | 0.100 |
Why?
|
| HIV Infections | 1 | 2019 | 772 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 610 | 0.100 |
Why?
|
| Adenoma | 1 | 2012 | 235 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2021 | 3241 | 0.090 |
Why?
|
| Mice | 2 | 2021 | 11352 | 0.090 |
Why?
|
| Rabbits | 3 | 2000 | 636 | 0.090 |
Why?
|
| Genotype | 1 | 2014 | 1850 | 0.090 |
Why?
|
| Adolescent | 3 | 2017 | 8979 | 0.090 |
Why?
|
| Puerperal Disorders | 1 | 2009 | 32 | 0.080 |
Why?
|
| Obesity | 2 | 2015 | 963 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2021 | 504 | 0.080 |
Why?
|
| Dermatofibrosarcoma | 1 | 2008 | 13 | 0.080 |
Why?
|
| Porphyrins | 2 | 1998 | 39 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 827 | 0.080 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2007 | 54 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 806 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2012 | 849 | 0.070 |
Why?
|
| Support Vector Machine | 1 | 2023 | 25 | 0.060 |
Why?
|
| Apoptosis | 2 | 2021 | 1683 | 0.060 |
Why?
|
| Ulcer | 1 | 2022 | 36 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1804 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2000 | 188 | 0.050 |
Why?
|
| Hair Removal | 1 | 2002 | 14 | 0.050 |
Why?
|
| Sweat Glands | 1 | 2021 | 6 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2021 | 35 | 0.050 |
Why?
|
| Cold Temperature | 1 | 2002 | 157 | 0.050 |
Why?
|
| Daunorubicin | 1 | 2021 | 78 | 0.050 |
Why?
|
| Mercaptopurine | 1 | 2021 | 53 | 0.050 |
Why?
|
| Leg Ulcer | 1 | 2001 | 7 | 0.050 |
Why?
|
| Cytarabine | 1 | 2021 | 218 | 0.050 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2001 | 19 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 299 | 0.050 |
Why?
|
| Ischemia | 1 | 2022 | 243 | 0.050 |
Why?
|
| Erythema | 2 | 1997 | 27 | 0.050 |
Why?
|
| Pruritus | 1 | 2000 | 26 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2001 | 234 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 392 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2001 | 172 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2000 | 94 | 0.040 |
Why?
|
| Software | 1 | 2024 | 654 | 0.040 |
Why?
|
| Lymphangiogenesis | 1 | 2018 | 38 | 0.040 |
Why?
|
| Maximum Allowable Concentration | 1 | 1997 | 2 | 0.040 |
Why?
|
| Protoporphyrins | 1 | 1997 | 19 | 0.040 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1997 | 41 | 0.040 |
Why?
|
| Fluorescence | 1 | 1997 | 102 | 0.040 |
Why?
|
| Edema | 1 | 1997 | 71 | 0.040 |
Why?
|
| Nocardia | 1 | 2016 | 2 | 0.040 |
Why?
|
| Light | 1 | 1997 | 289 | 0.030 |
Why?
|
| Recurrence | 2 | 2014 | 1139 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1830 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 33 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 894 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1583 | 0.030 |
Why?
|
| Time Factors | 3 | 2002 | 5209 | 0.030 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 29 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2600 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2015 | 207 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1019 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 770 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 943 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 1989 | 34 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1989 | 135 | 0.020 |
Why?
|
| Furocoumarins | 1 | 2007 | 2 | 0.020 |
Why?
|
| New Hampshire | 1 | 2007 | 3 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2007 | 22 | 0.020 |
Why?
|
| Diet | 1 | 1989 | 443 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 193 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2002 | 41 | 0.010 |
Why?
|
| Skin, Artificial | 1 | 2001 | 8 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 3611 | 0.010 |
Why?
|
| Liposomes | 1 | 1998 | 91 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2001 | 996 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1998 | 290 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1998 | 81 | 0.010 |
Why?
|
| Iontophoresis | 1 | 1997 | 9 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1997 | 242 | 0.010 |
Why?
|
| Models, Biological | 1 | 1998 | 1749 | 0.010 |
Why?
|
| Plant Oils | 1 | 1989 | 9 | 0.010 |
Why?
|
| Occupations | 1 | 1989 | 26 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1989 | 364 | 0.010 |
Why?
|
| Smoking | 1 | 1989 | 609 | 0.000 |
Why?
|